Spots Global Cancer Trial Database for ibrutinib
Every month we try and update this database with for ibrutinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | NCT03513562 | Chronic Lymphoc... Ibrutinib Resis... | Ibrutinib Laboratory Biom... Venetoclax | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01886859 | Recurrent B-Cel... Recurrent Chron... Recurrent Small... Refractory B-Ce... Refractory Chro... Refractory Smal... | Ibrutinib Lenalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. | NCT02315768 | Chronic Lymphoc... | GA101 ibrutinib | 65 Years - | University of California, San Diego | |
| Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | NCT05106296 | Ependymoma Medulloblastoma Glioblastoma Primary Brain T... | Ibrutinib Indoximod Cyclophosphamid... Etoposide | 12 Years - 25 Years | Augusta University | |
| A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma | NCT01569750 | CD20-positive B... | Part 1, Cohort ... Part 1, Cohort ... Part 1, Cohort ... Part 2, Cohort ... Part 2, Cohort ... | 18 Years - | Janssen Research & Development, LLC | |
| Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL | NCT02973399 | Cancer | SNX-5422 plus i... | 18 Years - | Esanex Inc. | |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma | NCT03479268 | B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom... | Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological... | 18 Years - | City of Hope Medical Center | |
| Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma | NCT02689869 | Indolent Non-Ho... | Ibrutinib GA 101 | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) | NCT04608318 | Chronic Lymphoi... | Ibrutinib Venetoclax Obinutuzumab | 18 Years - | German CLL Study Group | |
| LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) | NCT04446962 | Lymphoma, Large... Central Nervous... | Lenalidomide Ibrutinib | 18 Years - 65 Years | Institut Curie | |
| A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01776840 | Mantle Cell Lym... | Bendamustine Rituximab Ibrutinib Placebo | 65 Years - | Janssen Research & Development, LLC | |
| Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma | NCT03219047 | Recurrent Mantl... Refractory Mant... | Best Practice Ibrutinib Patient Derived... Personalized Me... | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | NCT02406742 | Leukemia, Lymph... | CC-122 Ibrutinib Obinutuzumab | 18 Years - 79 Years | Celgene | |
| Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML | NCT03642236 | FLT3-ITD Mutati... Acute Myeloid L... Brutons Tyrosin... | Ibrutinib | 14 Years - 60 Years | Nanfang Hospital, Southern Medical University | |
| A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01611090 | Chronic Lymphoc... Small Lymphocyt... | Ibrutinib Bendamustine hy... Rituximab Placebo | 18 Years - | Janssen Research & Development, LLC | |
| Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma | NCT02142049 | Diffuse Large B... Diffuse Large B... | Ibrutinib DA-EPOCH-R Lenalidomide | 18 Years - | Pharmacyclics LLC. | |
| A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants | NCT01674322 | Healthy Partici... | Ibrutinib | 30 Years - 55 Years | Janssen Research & Development, LLC | |
| Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients | NCT02912754 | Leukemia, Lymph... | ruxolitinib ibrutinib | 19 Years - | Sunnybrook Health Sciences Centre | |
| Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant | NCT03015792 | Recurrent Plasm... Refractory Plas... | Dexamethasone Ibrutinib Laboratory Biom... Lenalidomide Pharmacological... Quality-of-Life... | 18 Years - | Mayo Clinic | |
| Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas | NCT03220022 | AIDS-Related Ly... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... | Cyclophosphamid... Doxorubicin Hyd... Etoposide Filgrastim Ibrutinib Laboratory Biom... Pegfilgrastim Pharmacological... Prednisone Rituximab Vincristine Sul... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing | NCT02604511 | Waldenstrom's M... | Ibrutinib | 18 Years - | Dana-Farber Cancer Institute | |
| Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma | NCT05998642 | Non-hodgkin Lym... | Methotrexate Rituximab (wher... Ibrutinib | 18 Years - | Canadian Cancer Trials Group | |
| Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | NCT02940301 | Classical Hodgk... | Ibrutinib Laboratory Biom... Nivolumab | 19 Years - | Ohio State University Comprehensive Cancer Center | |
| Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia | NCT03447808 | Chronic Lymphoc... | Daratumumab Ibrutinib Laboratory Biom... Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma | NCT02581930 | Metastatic Mela... Recurrent Cutan... Stage IV Cutane... | Ibrutinib Laboratory Biom... Pharmacogenomic... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma | NCT01974440 | Lymphoma | Bendamustine Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone PCI-32765 (Ibru... Placebo | 18 Years - | Janssen Research & Development, LLC | |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | NCT04739813 | Lymphoma Non-Hodgkin Lym... Diffuse Large B... Burkitt Lymphom... | obinutuzumab prednisone Revlimid Polatuzumab ibrutinib venetoclax | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma | NCT04234061 | Mantle Cell Lym... | ibrutinib and T... | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy | NCT01599949 | Mantle Cell Lym... | Ibrutinib | 18 Years - | Janssen Research & Development, LLC | |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05105841 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Ibrutinib Obinutuzumab | 20 Years - | AbbVie | |
| Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant | NCT02662296 | Prolymphocytic ... Recurrent Chron... Recurrent Non-H... Recurrent Small... | Ibrutinib Idelalisib | 18 Years - | Fred Hutchinson Cancer Center | |
| Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT02518555 | Chronic Lymphoc... Small Lymphocyt... | Diphtheria Toxo... Ibrutinib Laboratory Biom... Pharmacological... Pneumococcal 13... Quality-of-Life... Trivalent Influ... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT02048813 | Anemia Chronic Lymphoc... Small Lymphocyt... | Cyclophosphamid... Fludarabine Pho... Ibrutinib Laboratory Biom... Pharmacogenomic... Quality-of-Life... Rituximab | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL | NCT03949062 | Diffuse Large B... | Ibrutinib Lenalidomide Rituximab | 75 Years - | Ruijin Hospital | |
| Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome | NCT02553941 | Chronic Myelomo... de Novo Myelody... Previously Trea... Refractory Anem... Secondary Myelo... | Azacitidine Ibrutinib | 18 Years - | University of California, Davis | |
| A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting | NCT03720561 | Leukemia, Lymph... | Ibrutinib | 18 Years - | Janssen-Cilag S.p.A. | |
| Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis | NCT03130348 | Amyloidosis Immunoglobulin ... | Bortezomib Dexamethasone Ibrutinib Laboratory Biom... | 18 Years - | Mayo Clinic | |
| Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT03702725 | Refractory Mult... Multiple Myelom... Multiple Myelom... | Ibrutinib Lenalidomide Dexamethasone | 18 Years - | Alliance Foundation Trials, LLC. | |
| Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) | NCT03964090 | Central Nervous... Secondary Centr... | TEDD-R TEDDI-R Ibrutinib Cytarabine Isavuconazole Methotrexate | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | NCT05283720 | Non-Hodgkin Lym... | Epcoritamab Lenalidomide Ibrutinib Rituximab Cyclophosphamid... Doxorubicin Hyd... Prednisone Polatuzumab Ved... Venetoclax CC-99282 | 18 Years - | Genmab | |
| Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy | NCT02649387 | Stage I Chronic... Stage II Chroni... Stage III Chron... Stage IV Chroni... | Ibrutinib Laboratory Biom... | 18 Years - | Mayo Clinic | |
| Ublituximab + Ibrutinib in Select B-cell Malignancies | NCT02013128 | Chronic Lymphoc... Mantle Cell Lym... | Ublituximab Ibrutinib | 18 Years - | TG Therapeutics, Inc. | |
| A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy | NCT03301207 | Leukemia, Lymph... | Ibrutinib OC: Ethinylestr... Bupropion Midazolam | 18 Years - | Janssen Research & Development, LLC | |
| Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma | NCT03093831 | Lymphoma, B-Cel... | Ibrutinib | 21 Years - 99 Years | National Cancer Centre, Singapore | |
| A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | NCT06136559 | Chronic Lymphoc... Small Lymphocyt... | Nemtabrutinib Ibrutinib Acalabrutinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma | NCT01974440 | Lymphoma | Bendamustine Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone PCI-32765 (Ibru... Placebo | 18 Years - | Janssen Research & Development, LLC | |
| Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma | NCT03232307 | CCND1 Positive CD20-Positive N... Mantle Cell Lym... | Dexamethasone Ibrutinib Lenalidomide Rituximab | 66 Years - | M.D. Anderson Cancer Center | |
| A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma | NCT01779791 | Lymphoma | PCI-32765 (Ibru... | 18 Years - | Janssen Research & Development, LLC | |
| Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT02219737 | CD20 Positive Recurrent Diffu... Refractory Diff... | Carboplatin Etoposide Ibrutinib Ifosfamide Laboratory Biom... Pharmacological... Rituximab | 18 Years - | National Cancer Institute (NCI) | |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | NCT04043845 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... | Ibrutinib LY3214996 | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 | NCT04274738 | Waldenstrom's M... | Mavorixafor Ibrutinib | 18 Years - | X4 Pharmaceuticals | |
| A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies | NCT02352558 | Hematologic Mal... | BBI608 Dexamethasone Bortezomib Imatinib Ibrutinib | 18 Years - | Sumitomo Pharma America, Inc. | |
| A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma | NCT02954406 | Lymphoma, Non-H... | TAK-659 Bendamustine Rituximab Gemcitabine Lenalidomide Ibrutinib | 18 Years - | Takeda | |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) | NCT02801578 | Chronic Lymphoc... | Ibrutinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT02537613 | Chronic Lymphoc... | Obinutuzumab Ibrutinib | 18 Years - | Dana-Farber Cancer Institute | |
| Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization | NCT04439006 | Aplastic Anemia Hematopoietic a... Malignant Solid... Monoclonal B-Ce... Monoclonal Gamm... Myelodysplastic... Symptomatic COV... | Best Practice Ibrutinib | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma | NCT03479268 | B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom... | Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological... | 18 Years - | City of Hope Medical Center | |
| Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years | NCT05406154 | Mantle Cell Lym... | 60 Years - | Peking University Third Hospital | ||
| Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib | NCT02636322 | Diffuse Large B... | Cyclophosphamid... Doxorubicin Hyd... Etoposide Ibrutinib Lenalidomide Prednisone Rituximab Vincristine Sul... | 18 Years - | M.D. Anderson Cancer Center | |
| Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma | NCT03939182 | Diffuse Large B... Mantle Cell Lym... | Abexinostat Ibrutinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma | NCT02356458 | Mantle Cell Lym... | Ibrutinib bortezomib | 18 Years - | Swiss Group for Clinical Cancer Research | |
| A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas | NCT02401048 | Diffuse Large B... Follicular Lymp... | Ibrutinib MEDI4736 | 18 Years - | Pharmacyclics LLC. | |
| TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma | NCT02927964 | Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Folli... Refractory Foll... Mantle Cell Lym... Marginal Zone L... | Ibrutinib Radiation Thera... TLR9 Agonist SD... | 18 Years - | Stanford University | |
| A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting | NCT03720561 | Leukemia, Lymph... | Ibrutinib | 18 Years - | Janssen-Cilag S.p.A. | |
| Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT02048813 | Anemia Chronic Lymphoc... Small Lymphocyt... | Cyclophosphamid... Fludarabine Pho... Ibrutinib Laboratory Biom... Pharmacogenomic... Quality-of-Life... Rituximab | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Biomarker Guided Treatment in DLBCL | NCT04025593 | Diffuse Large B... | Cyclophosphamid... Rituximab Doxorubicin Vincristine Prednisone Ibrutinib Lenalidomide chidamide decitabine | 18 Years - 80 Years | Ruijin Hospital | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma | NCT01962792 | Multiple Myelom... | Ibrutinib Carfilzomib Dexamethasone | 18 Years - | Pharmacyclics LLC. | |
| A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) | NCT03053440 | Waldenström's M... | BGB-3111 Ibrutinib | 18 Years - | BeiGene | |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | NCT03223610 | Lymphoma Non-Hodgkin Lym... Diffuse Large B... Burkitt Lymphom... | Venetoclax Ibrutinib Prednisone Obinutuzumab Revlimid (lenal... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant | NCT02869633 | Blastoid Varian... Recurrent Chron... Recurrent Folli... Recurrent Hodgk... Recurrent Mantl... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Mant... | Ibrutinib Laboratory Biom... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | NCT02007044 | Prolymphocytic ... Recurrent Chron... Recurrent Small... | Ibrutinib Quality-of-Life... Questionnaire A... Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia | NCT06299540 | Leukemia, Lymph... | Individual Phys... Ibrutinib | 18 Years - | Janssen Cilag S.A.S. | |
| Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients | NCT02912754 | Leukemia, Lymph... | ruxolitinib ibrutinib | 19 Years - | Sunnybrook Health Sciences Centre | |
| A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | NCT02403271 | Non-Small Cell ... Breast Cancer Pancreatic Canc... | Ibrutinib Durvalumab | 18 Years - | Pharmacyclics LLC. | |
| Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01880567 | CCND1 Positive CCND2 Positive CCND3 Positive CD20 Positive Mantle Cell Lym... Recurrent Mantl... Refractory Mant... | Ibrutinib Laboratory Biom... Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients | NCT02943473 | High Risk Smold... | Ibrutinib | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia | NCT01841723 | Hairy Cell Leuk... Hairy Cell Leuk... Recurrent Hairy... | Ibrutinib | 18 Years - | National Cancer Institute (NCI) | |
| Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) | NCT02315326 | Adult Patients ... Or Relapsed or ... | Ibrutinib HD- Methotrexat... Rituximab + HD-... procarbazine | 18 Years - | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
